SOPHARMA AD - CORRECTION Current report 2 re 2011 results (2/2012)

| | POLISH FINANCIAL SUPERVISION AUTHORITY | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | | | | UNI - EN REPORT No | 2 | / | 2012 | | | | |
| | Date of issue: | 2012-01-05 | | | | | | | | | |
| | Short name of the issuer | | | | | | | | | | |
| | SOPHARMA AD | | | | | | | | | | |
| | Subject | | | | | | | | | | |
| | CORRECTION Current report 2 re 2011 results | | | | | | | | | | |
| | Official market - legal basis | | | | | | | | | | |
| | Art. 56 ust. 1 pkt 1 Ustawy o ofercie - informacje poufne | | | | | | | | | | |
| | Unofficial market - legal basis | | | | | | | | | | |
| | Contents of the report: | | | | | | | | | | |
| | Dear Sir or Madam, In compliance with art. 100k., para. 1 from the POSA, we would like to notify that for the month of December, 2011 Sopharma AD realized growth of sales revenues of 38% compared with the same month of the previous year, including 48% growth of domestic sales and 29% growth of export sales. The economic and political environment in Europe, the echo of the world crises and a number of administrative obstacles limited the growth rates during 2011. Sales revenues reached almost 210 million BGN and grew with 0.41%, including 3.32% growth of the domestic market and 0.86% decrease of exports compared with the same period of 2010. ?The past year forced us to adopt a management approach of balance between innovative investments in the company?s future, strengthening our positions at the existing markets and a conservative standing towards entirely new initiatives. During the second half of 2011 we came across a number of administrative problems, which disrupted our export to Russia and other
significant markets. After some of these issues were solved in December 2011 we managed to realize double digit growth for Caucuses and Middle Asia, the Balkan region, Moldova, as well as growth in the export sales for the Ukraine and the Baltic states. In the first months of 2012, having all the necessary documents and licenses we expect that sales revenues will compensate the downturn in the last months of the previous year and will give us a good start of this not less challenging year." commented the executive director of Sopharma AD, Ognian Donev PhD. In accordance with the provisions of art. 100 k., para. 1 from the POSA, please make the aforementioned information public. 05.01.2012 Pelagia Viatcheva /IR Director, Sopharma AD/ | | | | | | | | | | |
| | Annexes | | | | | | | | | | |
| | File | Description | | | | | | | | | |
| | Current report 2 re 2011 results.docx | Current report 2 re 2011 results | | | | | | | | | |

REPORT
INFORMATION ABOUT THE ENTITY
SIGNATURE OF PERSONS REPRESENTING THE COMPANY

| | | SOPHARMA AD | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| | | (fullname of the issuer) | | | | | |
| | | SOPHARMA AD | | Farmaceutyczny (far) | | | |
| | | (short name of the issuer) | | (sector according to clasification of the WSE in Warsow) | | | |
| | | 1220 | | Sofia | | | |
| | | (post code) | | (city) | | | |
| | | IlienskoShosse | | 16 | | | |
| | | (street) | | (number) | | | |
| | | +359 2 813 42 00 | | +359 2 936 02 86 | | | |
| | | (phone number) | | | (fax) | | |
| | | (e-mail) | | | (web site) | | |
| | | nd | | | | | |
| | | (NIP)
| | | (REGON) | | |

REPORT
INFORMATION ABOUT THE ENTITY
SIGNATURE OF PERSONS REPRESENTING THE COMPANY